Nitrazepam
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01595 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | sleep disorder, initiating and maintaining sleep | KG + DL |
| 2 | acute encephalopathy with biphasic seizures and late reduced diffusion | KG + DL |
| 3 | Wernicke-Korsakoff syndrome | KG + DL |
| 4 | restless legs syndrome | KG + DL |
| 5 | alcohol withdrawal | KG + DL |
| 6 | anxiety | KG + DL |
| 7 | epilepsy, childhood absence, susceptibility to | KG + DL |
| 8 | benign paroxysmal torticollis of infancy | KG + DL |
| 9 | anxiety disorder | KG + DL |
| 10 | alcohol withdrawal delirium | KG + DL |
| 11 | agoraphobia | KG + DL |
| 12 | antidepressant type abuse | KG + DL |
| 13 | hallucinogen abuse | KG + DL |
| 14 | barbiturate abuse | KG + DL |
| 15 | phencyclidine abuse | KG + DL |
| 16 | channelopathy-associated congenital insensitivity to pain, autosomal recessive | KG + DL |
| 17 | dysthymic disorder | KG + DL |
| 18 | cauda equina syndrome | KG + DL |
| 19 | myoclonic-atonic epilepsy | KG + DL |
| 20 | attention deficit-hyperactivity disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.